Clinical Implementation of Auto-Planning

Ping Xia, Ph.D. Professor of Molecular Medicine Cleveland Clinic, Cleveland



Disclosures

É Philips: Research Grant É Siemens: Research Grant



Clinic Demands Efficiency and Quality Cares

- É One of 2015øs themes at Cleveland Clinic is to improve patient access.
- É From Cancer Center, we aim to reduce time from cancer diagnosis to treat.
- É From Radiation Oncology, we aim to reduce time from simulation to treat.

Cleveland Clinic Clinical Workflow and Timeline



Cleveland Clinic

Why Auto-Planning?

- ó IMRT planning requires constant real time tuning of the planning objectives and extra contours ó Chinese Cooking method
- ó Highly dependent on how and when these tuning planning objectives and contours are added in optimizer - cooking process.
- ó It depends anatomical relationship among the OARs and PTVs cooking ingredients.



What Is Auto-Planning (AP)

- É AP is a new IMRT planning module in Pinnacle system, released in version 9.10.
- É Users can create their own cancer specific, machine specific, or IMRT delivery method specific AP technique to speed up IMRT planning ó recipe method
- É Users can also use AP to perform IMRT optimization while setting other planning parameters such as beam angles, delivery method (step and shoot vs. VMAT) ó spontaneous method

My Early Experience in 2003



Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 3, pp. 886–896, 2004 Copyright © 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/\$-see front matter

doi:10.1016/j.ijrobp.2004.02.040

PHYSICS CONTRIBUTION

A STUDY OF PLANNING DOSE CONSTRAINTS FOR TREATMENT OF NASOPHARYNGEAL CARCINOMA USING A COMMERCIAL INVERSE TREATMENT PLANNING SYSTEM

PING XIA, PH.D., NANCY LEE, M.D., YU-MING LIU, M.D., IAN POON, M.D., VIVIAN WEINBERG, PH.D., EDWARD SHIN, M.D., JEANNE M. QUIVEY, M.D., AND LYNN J. VERHEY, PH.D.

Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA



I was Skeptical

- É Auto-Planning could only work for simple cases
- É Ideal candidates include sites with small variations in tumor shape and location prostate cancer, possibly nasopharynx cancer.
- É Challenging sites include head and neck cancer with variations in tumor shapes and locations.



Example 1

É Oral Cavity Case
É Rx dose: 64 Gy, 60 Gy, and 54 Gy.
É Nine beams used in the clinical plan,
É Nine beam used in the auto-plan Step and Shoot (SS) plan
É 2 arcs used in auto-VMAT plan



Clinical PlanAuto-Plan SSAuto-Plan VMAT



68.0, **64.0**, **60.0**, **54.0**, **45.0**, **35.0**





Example 2

É Larynx Cancer
É Rx: 70 Gy and 56 Gy
É Clinical Plan: Nine beam angles
É Auto Plan: Nine beam Angles step and shoot (SS)
É Auto Plan: 2 arc VMAT



Clinical PlanAuto-Plan SSAuto-Plan VMAT



77.0, 70.0, 56.0, 45.0, 35.0 Gy



Comparison of HN Plans (n=7)

		Clinical	AP_IMRT	AP_VMAT	Clinical vs. AP_IMRT p-value	Clinical vs. AP_VMAT p-value
HD_PTV	V _{706v} (%)	95.5	95.5	95.5	0.643	0.884
LD_PTV	V _{56Gv} (%)	96.5	98.5	98.7	<0.001	0.001
Brainstem	D _{max} (Gy)	30.7	24.7	20.4	0.016	0.012
Spinal_cord	D _{max} (Gy)	40.7	40.0	37.9	0.703	0.339
Paratid_L	D _{mean} (Gy)	31.8	28.4	27.2	0.213	0.091
Paratid_R	D _{mean} (Gy)	32.4	28.3	26.6	0.109	0.032
Larynx	D _{mean} (Gy)	41.1	30.07	29.3	0.014	0.008
Trachea	D _{mean} (Gy)	26.6	21.6	22.0	0.030	0.036
Esophagus	D _{mean} (Gy)	25.6	17.3	17.2	0.002	0.001
н		1.11	1.13	1.10	0.154	0.314
C		1.14	1.12	1.01	0.746	0.003

Prostate

É High risk Prostate É Rx: 78 Gy to prostate-PTV, 66 Gy to SV É Clinical Plan: 7 beam angles É Auto-Plan: 2 arc VMAT



Clinical Plan Auto-VMAT te)

80.0, 78.0, 70.0, 66.0, 45.0, 25.0 Gy





Prostate and Pelvic Lymph Nodes (n=8)

		Clinical plan (mean \pm SD)	Auto-plan (mean \pm SD)	p-value
PTV_prostate	V _{70Gv} (%)	95.3 ± 0.1	95.4 ± 0.1	0.310
PTV_SV	V _{60/56Gy} (%)	96.3 ± 2.8	99.7 ± 0.4	0.012
PTV_LN	V _{50.4/45Gy} (%)	93.3 ± 3.4	96.4 ± 1.7	0.067
Bladder	V _{63Gy} (%)	8.9 ± 4.0	9.2 ± 3.7	0.274
Rectum	V _{63Gy} (%)	11.8 ± 2.7	9.1 ± 1.9	0.016
Rectum	V _{45Gy} (%)	39.2 ± 8.6	25.2 ± 3.3	0.005
Penile bulb	D _{mean} (Gy)	38.2 ± 15.8	25.6 ± 13.6	0.001
HI		1.06 ± 0.01	1.08 ± 0.01	0.006
Cl		1.00 ± 0.03	1.00 ± 0.02	0.888

How it works

É Mimics the plannersøthought process
É Utilizes the plannersøtricks, such as creation of surrounding structures, tuning contours automatically

É Automatically runs multiple loops while adjusting planning objectives ó similar to what planners manually do



No More Negotiation With Optimizer

- É IMRT planning was a process of negotiating with the optimizer.
 - ó Adding tuning structures, cold spots, and hot spots.
- É Auto-Planning allows us to simply state the dosimetric planning goals
- É Auto-Planning automatically creates planning objectives and tuning structures that are required.



A Complex HN case

É 40 structures (include two tumor volumes) were contoured.

- É 28 dose evaluation goals were input into auto-planning.
- É 26 additional tuning structures were automatically created.
- É 74 optimization objectives were automatically set for optimization.



<u>or</u>	Treatme	nt Techniques		
File Passalag Bessar Auto-Plan Description	tion For Auto-Planning	Trial to Cr	eate AP_WMAT_PELVIS	S ?
Auto-Planning Settings Max Iterations Engine Type 50 • Biological Non-Biological Advanced Settings Target Optimization Goals ROI Dose CGy Total PTV I (4500	Organ At Risk (OAR) Optin ROI	nization Goals	Dose cGy Volume (%) [4000 [30 [4000 [80 [4500 [35 [1000 [90 [4000 [37	Priority Compromise Medium I I Medium I I Medium I I Medium I I I
Add Delete	Add Delete			
			Apply	Apply and Optimize

An Example of Planning Goals for OARs

Orga	ROI	ization (Goals Type	Dose cGy	Volume (%)	Priority
Ŷ	OPTIC_NRV_R	-	Max Dose 💷	Ĭ5400		High 💷
Ŷ	ORAL_CAVITY	=	Mean Dose 💷	[3000		Medium 🖃
Ŷ	PAROTID_R	-	Mean Dose 💷	[2500		High 💷
Ŷ	SPINAL_CORD	-	Max Dose 💷	Ĭ 4200		High 💷
¢	SPINAL_CORD_PRV	-	Max Dose 💷	[4500		High 💷



AP Spine SBRT



16 Gy,12 Gy,10 Gy



Advance Tool Setting





Input Planning Goals

Targe	et Optimization Goals	Dose
	ROI	cGy
*	T2-4 Tumor 🗖	<u>1600</u>

Org	an At Risk (OAR) Optim	nization	Goals	Dose	Volume			
	ROI		Туре	cGy	(%)	Priority		Compromise
•	Cord T2-4		Max Dose 💷	ľ 1350		High	-	
¢	C7 - 74 cord		Max DVH 💷	Ĭ 1000	Ĭ5	High		
\$	Cord T2-4		Max DVH 💷	Ĭ900	Ĭ2	High		
\$	Ring_5mm_T2		Max DVH 🗖	1400	Ĭ 10	High		
\$	ring_2cm_T2		Max DVH 🗖	1000	Ĭ 10	High		
\$	ESOPHAGUS		Max Dose 💷	Ĭ 1600		High		

Automatic Created Planning Objectives

	Ĭ 1600	[20 [0.104445	
	I 1600	Ĭ20 (0.0647136	
♦ T2-4 Tumor_AP_	Ĭ2567.48	ž35 z	2.80684 e -06	
TargetSurround_/= Assd_07 - 14 cc = N	tax DVH ⊐ ☐ [490.509	Ĭ5	[0.125 0.01674	
TargetSurround_/=	lax Dose 🖃 🗍 [894.451		0.125 0.0189307	
	lax DVH = [998.786	Ĭ10	[0.125] 0.013325	
	lax DVH = 1260	Ĭ10	1.46928 I.46928	
↓ T2-4 Tumor_AP_■	SodyMinusTarget Max Dose		<u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u>	100 5.63819
◆ T2-4 Tumor_AP_■	BodyMinusTarget Max Dose		<u></u> [286.574	0.0991067
		= =	<u>]</u> 900 <u>]</u> 5	
	♀ Cord T2-4 □ Max DVH	= =	<u></u> [648.938][5	[0.125 0.00602535
	Cord T2-4 I Max DVH		<u></u> [810][5	<u> </u>
	Cord T2-4 II Max Dose		Ĭ1215	100 0.144602
	Cord T2-4 I Max Dose		Ĭ 746.603	<u>10.125</u> 0.00694334



Lung SBRT

- É Re-planned 20 SBRT lung cases, 10 for peripheral tumors and 10 for central tumors.
 É Ask physicians to rank quality of AP vs. Clinical plans.
- É 15% AP plans are better, 80% AP plans are comparable, and 5% AP plans are worse than clinically approved plans.



Manual Plan











50 35 25 10 Gy



Central Lung SBRT



Do We Know What We Want to Achieve in IMRT Planning?



CCF Cancer Specific Treatment Planning Guidelines and Dose Constraints

Cancer Specific IMRT Treatment Planning Constraints and Guidelines

Cancer Specific IMRT Treatment Planning Constraints and Guidelines

Patient Name	
Patient ID	Patient Name
Freatment Site	Patient ID
Prescription do	Treatment Site:
Organ Name	Prescription dose
Organ Name	Organ Name
CTV_504	GTV_7000
PTV_504	CTV_7000
ITV_504	CTV_7000
KIDNEY	PTV_7000
KIDNEY	PTV_7000
KIDNEY	PTV_7000
	CTV_5600
KIDNEY_	PTV_5600
KIDNEY	BRAIN
KIDNEY_	BRAIN
SM BOW	BRAINSTEN
SM BOW	BRAINSTEN
SM BOW	CHIASM
STOMAC	COCHLEA_I

	Departme	ent of Radiation Oncolo	gy Cleveland Clinic						
23 forms									
organ Name	Enapoint 1	constraints	Planned	comments					
CTV_7800	V7800 cGy	> 99%							
Or	Foun	d in in	RTOG	G/NRG					
Or	Foun	d in in Protoc	RTOG ols	/NRG					
RECTUM	Foun	d in in Protoc	RTOG ols	S/NRG					
RECTUM	Foun D10cc V5000 cGy	d in in Protoc <7000 cGy < 30%	RTOG ols	Without pelvic nodes					
RECTUM RECTUM	D10cc V5000 cGy	d in in Protoc <7000 cGy <30% <50%	RTOG ols	Without pelvic nodes With pelvic no					
RECTUM RECTUM RECTUM FEMORAL HEAD_L	D10cc V5000 cGy V5000 cGy V5000 cGy	d in in Protoc < 7000 cGy < 30% < 50% < 5%	RTOG	Without pelvic nodes With pelvic no					
RECTUM RECTUM RECTUM FEMORAL HEAD_L FEMORAL HEAD_R	D10cc V5000 cGy V5000 cGy V5000 cGy V5000 cGy	d in in in protoco	RTOG	Without pelvic nodes With pelvic no					

.

Pinnacle plan DVH information

CCF Pinnacle ³⁶ Plan Evaluation

ROI	EndPoint	Constraint	Plan	
	(cGy/Vol)	(cGy/Vol)	(cGy/Vol)	
PTV_6400	V6400	>95%	95.6%	
CTV_6400	V6400	>98%	98.0%	
PTV_6000	V6000	>95%	98.7%	
CTV_6000	V6000	>98%	99.9%	
PTV_5400	V5400	>95%	95.6%	
CTV_5400	V5400	>98%	99.2%	
BRAIN	D0.03CC	<6400	6649.8	
BRAIN	V6000	<33%	0.1%	
BRAINSTEM	D0.03CC	<5400	2631.5	
BRAINSTEM	V3000	<50%	0.0%	
COCHLEA_L	D0.03CC	<5500	1292.6	
COCHLEA_R	D0.03CC	<5500	4078.8	

ESOPHAGUS	DMEAN	<5000	2082.7	
GLOBE_L	D0.03CC	<4500	1185.0	
GLOBE_R	D0.03CC	<4500	2448.0	
LARYNX	DMEAN	<3500	3417.0	
LENS_L	D0.03CC	<1000	625.0	
LENS_R	D0.03CC	<1000	690.6	
LIPS	DMEAN	<3500	5129.9	
MANDIBLE	D0.03CC	<7500	6808.0	
MANDIBLE	V7000	<]%	0.0%	
ORAL_CAVITY_PTV	D0.03CC	<6000	6811.3	
ORAL_CAVITY_PTV	DMEAN	<3500	4354.0	
PAROTID_L_PTV	V3000	<50%	22.4%	
PAROTID_L_PTV	DMEAN	<2600	1936.1	
PAROTID_R_PTV	V3000	<50%	33.6%	
PAROTID_R_PTV	DMEAN	<2600	2652.1	
SPINAL_CORD	D0.03CC	<4500	4148.1	

Quantitative Plan Evaluation - Score Cards

			ROI	D	T∨ne		Dose cGv		Volum	e	Dose cGv	voiune d	√olume	Dose cGv	Primary C	Goal	Result
	ROI	Туре		cGy	Volume		cGy	Volume		cGy		Primary G Dose	ioal	Result		,	Not Met
Ŷ	GTV 7200 💆	Min DVH (%)		Ĭ7200	Ĭ 99	%	ĬO	ĬO	%	7260.9	Min	99.998	%	Met		5	Met
Ŷ]CTV_7200	Min DVH (%)		Į7200	[98	%	ĬO	ĬO	%	7234.6	Min	99.998	%	Met		5	Met
Ŷ]CTV_7200 ⊻	Min DVH (%)		Ĭ6700	Ĭ 99	%	ĬO	ĬO	%	7234.6	Min	99.998	%	Met		m^3	Met
÷	ĬPTV_7200 ⊻	Max DVH (cm^3	3) 🗆	Ĭ8200	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	7745.0	Max	0.000	cm^3	Met		5	Not Met
Ŷ]PTV_7200 ⊻	Min DVH (%)	-]7200	[95	%	ĬO	ĬO	%	3944.2	Min	95.545	%	Met		5	Met
Ŷ]PTV_7200 ⊻	Min DVH (%)		Ĭ6700	Ĭ 98	%	ĬO	ĬO	%	3944.2	Min	99.895	%	Met		5	Met
Ŷ	jctv_5800 ⊻	Min DVH (%)	-	Ĭ5800] 99	%	ĬO	ĬO	%	5888.7	Min	99.998	%	Met		5	Met
Ŷ	[PTV_5800 ⊻	Min DVH (%)		<u>]</u> 5800	[95	%	ĬO	ĬO	%	1298.7	Min	98.819	%	Met		m^3	Met
Ŷ	BRAIN 🗾	Max DVH (cm^3	3) 💷	Ĭ7000	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	2606.0	Max	0.000	cm^3	Met		5	Met
Ŷ	JBRAIN 🗹	Max DVH (%)	-	Ĭ 6000] 33	%	ĬO	ĬO	%	2606.0	Max	0.000	%	Met		m^3	Met
ŵ	BRAINSTEM	Max DVH (cm^3	3) 💷	<u>]</u> 5400	I 0.03	cm^3	IO	ĬO	cm^3	1680.7	Max	0.000	cm^3	Met		5	Met
Ŷ	BRAINSTEM	Max DVH (%)	=	Ĭ3000	[50	%	ĬO	ĬO	%	1680.7	Max	0.000	%	Met		m^3	Met
Ŷ	ČHIASM 💆	Max DVH (cm^3	3) 💴	Ĭ5400	Ĭ 0.03	cm^3	Ĭ0	ĬO	cm^3	90.9	Max	0.000	cm^3	Met		m^3	Met
Ŷ	ĴCOCHLEA_L ⊻	Max DVH (cm^3	3) 🗆	Ĭ5500	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	349.7	Max	0.000	cm^3	Met		m^3	Met
Ŷ	ĬCOCHLEA_R ⊻	Max DVH (cm^3	3) 🗖	Ĭ5500	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	391.3	Max	0.000	cm^3	Met			Not Met
Ŷ		Mean Dose		[5000			IO			5507.2	Mean			Not Met			Met
Ŷ	ESOPHAGUS	Mean Dose		<u>]</u> 5000			ĬO			2395.9	Mean			Met		m^3	Met
Ŷ]ĞLOBE_L ⊻	Max DVH (cm^3	3) 💷	¥4500	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	248.3	Max	0.000	cm^3	Met		m^3	Met
Ŷ	ĞLOBE_R ⊻	Max DVH (cm^3	3) 💷	Ĭ 4500	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	237.8	Max	0.000	cm^3	Met			Not Met
Ŷ	JLARYNX ⊻	Mean Dose		Ĭ3200			ĬO			2836.3	Mean			Met		m^3	Met
Ŷ	JĬLENS_L ⊻	Max DVH (cm^3	3) 💷	I 1000	Ĭ 0.03	cm^3	ĬO	ĬO	cm^3	126.0	Max	0.000	cm^3	Met		m^3	Met
Ŷ]ĨLENS_R ⊻	Max DVH (cm^3	3) 🗆	I 1000	[0.03	cm^3	ĬO	ĬO	cm^3	125.2	Max	0.000	cm^3	Met		m^3	Met
		May DV/H (amos	»	17500	Ĭnna		Ĭo	Ĭn	1	7494.9	hdow	0.000	amóa	h dot			

How Are Total MUs Affected



AP for Multiple Brain Mets

É A patient with multiple brain mets (6 mets)
É Using a single iso-center and five non-coplanar arcs.
É Three RXs concurrently: 30 Gy, 27.5 Gy, and 25 Gy in five fraction.





Apply AP to An Unusual Case



Use two iso-centers and VMAT beams to produce the feathering regions.
With AP, dosimetrists can produced this complicated plan with two runs of AP optimizations.

Magic Button: Cure without Complications

- É Auto-Planning is a promising tool.
- É Auto-Planning will improve plan quality and reduce planning time
- É Leverages dosimetrists human power, relying on the computer for grunt work
- É Auto-Planning will demand more computational power, not human power.

What types of treatment plans can be created using the auto-planning in the Pinnacle?

20%	1.	Electron plans only
20%	2.	3D conformal plans only
20%	3.	Step and shoot IMRT plans only
20%	4.	VMAT IMRT plans only
20%	5.	Step-shoot and VMAT IMRT plan



What types of treatment plans can be created using the auto-planning in the Pinnacle?

- ^{0%} a. Electron plans only
- 0% b. 3D conformal plans only
- 0% c. Step and shoot IMRT plans only
- 0% d. VMAT IMRT plans only
- ^{0%} e. Step-shoot and VMAT IMRT plans

What is the advantage of auto-planning?

- 20% a. To improve work efficiency
- 20% b. To keep consistency in planning process
- 20% c. To replace dosimtrists entirely
- 20% d. To improve plan quality, efficiency, and consistency.
- 20% e. To learn from previous planning techniques

What is the advantage of auto-planning?

20%	1.	To improve work efficiency
20%	2.	To keep consistency in planning process
20%	3.	To replace dosimtrists entirely
20%	4.	To improve plan quality, efficiency, and consistency.
20%	5.	To learn from previous planning techniques



SAM Question 3

Which answer below includes most features of the autoplanning process

(a)To create models based on previous plans.
(b)To create multiple tuning structures automatically .
(c)To create optimization objectives automatically
(d)To run optimization multiple times
(e) (b, (c), and (d)

Which answer below includes most features of the auto-planning process

- 20% a. To create models based on previous plans.
- 20% b. To create multiple tuning structures automatically .
- 20% c. To create optimization objectives automatically
- 20% d. To run optimization multiple times
- 20% e. (b, (c), and (d)

SAM Question 4

Which statement below summaries common features of knowledge-based planning and auto-planning?

(a) Only knowledge-based planning propagates knowledge from expertsøplanning

(b) There is no common feature between the two methods.

(c) Only knowledge-based planning requires building a new model.

(d)Auto-planning is the same as the conventional IMRT planning.

(e) Both methods can improve plan quality, consistency, and efficiency.

Which statement below summaries common features of knowledge-based planning and auto-planning?

- ON a. Only knowledge-based planning propagates knowledge from expertsqplanning
- 0% b. There is no common feature between the two methods.
- 0% c. Only knowledge-based planning requires building a new model.
- 0% d. Auto-planning is the same as the conventional IMRT planning.
- e. Both methods can improve plan quality, consistency, and efficiency.

Acknowledgment

É Eric Murray, CMD, John Suh, M.D.
É Diana Mattson, CMD. Erin Murphy, M.D.
É Lisa Zickefoose, CMD.
É Matt Kolar. M.S.
É Zhilei Liu Shen, Ph.D.
É Sam Chao, M.D.

Clinical Implementation of Auto-Planning

Ping Xia, Ph.D. Professor of Molecular Medicine Cleveland Clinic, Cleveland

